I'm going to short this into the close. the offering price won't be near the closing price i can guarantee that and we'll hear AH, overnight or PM tmrw. good luck
trying to make it look like there was a big insider buy when it was granted as an option. they are trying there best to pump this. could get ugly after hours.
I'm sure a lot of people will short this into the close also in anti caption of that. very weird price action today, the risk is big AH IMO tho
but he attacks every piece of positive news, just like a bear or short
you are clearly short this stock, time to stop pretending. a lot has changed in that two years with the need and attitude towards this class of drug. Salix and Progenics have the safety data the FDA needs already, which is why they did not conduct further trials because they DONT NEED TO.
that is why they appealed the CRL, that is why the FDA granted the adcom because they know they should have allowed the label expansion
"The clinical trials for Relistor were impressive and I do not believe that there will be any problems in terms of obtaining approval for the expanded use of Relistor."
they have pumped the #$%$ out of this stock since last week in anticipation of tmrw, even trying to start buyout rumors.
people are hoping it will act like ZU did but there are a lot of fundamental differences and a lot of fundamentally BAD things with this stock
deserves to be double where it is now even before approval.
However, it appears the reason for the called advisory meeting is the currently submitted drug, Relistor, which is marketed by Salix (SLXP). Salix and its partner, Progenics (PGNX), are hoping for an expanded usage for this drug, however, the FDA has questions about the cardiac events noted in their expansion trials. In 2012, the FDA issued a CRL that requested additional testing for this drug that is delivered by injection.
The market for an effective OIC drug is huge. There are nearly 70 million patients in the five largest markets that are being prescribed opioids for the treatment of pain. For those being prescribed such opioids, nearly 80%, or 56 million, develop OIC. Of this number, 50%, or 28 million, find that a normal laxative provides them no relief from their OIC condition.
but still looks overpriced and way over valued
in Q1 was all above where stock price is now so at this level it seems like a real bargain. will definitely make a move pre adcom
right, its not actually a good thing if expenses are growing faster than revenue.
Sales and marketing account for 104% of revenue and revenue growth will be 100% this year but closer to 50% in 2015.
91 million shares eligible for sale all above IPO price are about to hit the market. just not a pretty picture right now
With every thing negative going on for the company - Ryan & Maniska's investigation - as well as the overall market flight from momo stocks - this trades 9x sales and guided DOWN - its hard to imagine they won't sell. and the main reason apart from the aforementioned is its still a good premium above the IPO price of $20 so insiders will still make nice $ by selling when they can. and there is definitely a big risk of further downside so why not bank some $?
they priced the IPO at $20 for a reason, thats a realistic price